glp-1 kansas city What needs to know about obesity drugs Medical Weight Loss in Kansas

Its also a good reason to bring up timing directly at a consultation your provider can help you weigh whether to treat now with an established option or whether your specific situation makes sense to revisit once newer formulations reach the market

Clinicians must remain cautious: GLP-1 RAs are not fertility treatments and should be discontinued before conception until safety data are robust

project, Bruce Merrifield asked me to find a subject Id be excited to work on for years

That is, in contrast with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, PF'3944 only requires monthly rather than weekly subcutaneous injections to achieve comparable weight loss

All references FDA: Concerns with unapproved GLP-1 drugs used for weight loss NEJM (2023): Retatrutide Phase 2 trial in obesity Eli Lilly: Phase 2 retatrutide results published in NEJM Eli Lilly (Dec 2025): Phase 3 TRIUMPH-4 topline results announcement ClinicalTrials.gov: NCT05882045 (TRIUMPH-3) Drugs.com: Retatrutide status & timeline Lilly Trials: TRIUMPH-3 summary page